Currently approved prophylactic HPV vaccines (Q37640113)

21 August 2017

1 reference

title

Currently approved prophylactic HPV vaccines (English)

1 reference

21 August 2017

Diane M Harper

1

1 reference

21 August 2017

1 December 2009

1 reference

Expert Review of Vaccines

21 August 2017

1 reference

21 August 2017

8

1 reference

21 August 2017

12

1 reference

21 August 2017

1663-1679

1 reference

The search for infectious causes of human cancers: where and why (Nobel lecture).

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Human papilloma virus infection prior to coitarche

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Seroprevalence of human papillomavirus type 16 in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Seroprevalence of human papillomavirus type 16 infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Diagnoses and outcomes in cervical cancer screening: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Classification of papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Health and economic implications of HPV vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Economic evaluation of human papillomavirus vaccination in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Cost-effectiveness of human papillomavirus vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

The treatment of CIN: what are the risks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Adversomics: the emerging field of vaccine adverse event immunogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Acute disseminated encephalomyelitis following vaccination against human papilloma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

CNS demyelination and quadrivalent HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

New technologies in cervical cytology screening: a word of caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.123

21 January 2018

Identifiers

DOI

10.1586/ERV.09.123

1 reference

21 August 2017

1 reference

PubMed ID

19943762